MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of...
$49,078K
(37.31%↑ Y/Y)
Net cash provided by
investing activities
$5,956K
(53.03%↑ Y/Y)
Canceled cashflow
$43,122K
Net change in cash
and cash...
-$16,656K
(-38.19%↓ Y/Y)
Canceled cashflow
$5,956K
Change in fair value of
warrant liabilities
$18,962K
Stock-based compensation
$2,202K
(-23.11%↓ Y/Y)
Non-cash lease expense
$83K
(9.21%↑ Y/Y)
Prepaid expenses and
other assets
-$12K
(98.34%↑ Y/Y)
Total operating
expenses
-$40,586K
Purchase of
available-for-sale short-term...
$43,122K
(35.39%↑ Y/Y)
Net cash used in
operating activities
-$22,612K
(-40.80%↓ Y/Y)
Canceled cashflow
$21,259K
Loss from operations
$40,586K
Net loss
-$39,025K
Canceled cashflow
$40,586K
Accounts payable,
accrued expenses and...
-$4,300K
(-78.94%↓ Y/Y)
Accretion of investment
discounts
-$460K
(33.53%↑ Y/Y)
Operating lease
liabilities
-$86K
(-16.22%↓ Y/Y)
something is missing
-$58,087K
Change in fair value of
warrant liabilities
$18,962K
Other income, net
-$2,562K
Back
Back
Cash Flow
source: myfinsight.com
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)